Condition: Limbal Stem Cell Deficiency · Sponsor: Claris Biotherapeutics, Inc.
This study will enroll subjects with qualifying limbal stem cell deficiency (LSCD). All subjects will receive CSB-001 investigational drug in either one or both study eyes. The study is comprised of two identical phases (Dosing Phase I and II) of test article dosing separated by a 31- to 40-day period, the Dosing Holiday, where no test article is administered. Dosing Phase II is followed by an observational, noninterventional phase (Observation Phase).
This description comes directly from the study's public registry record.
Central Operations Representative · 919-354-1299 · clinicaltrials@clarisbio.com
Always discuss trial participation with your own doctor first.
| Loma Linda University Eye Institute | Loma Linda, California, United States | Recruiting |
| Midwest Cornea Associates, LLC | Carmel, Indiana, United States | Recruiting |
| Francis Price Jr, MD | Indianapolis, Indiana, United States | Recruiting |
| Minnesota Eye Consultants | Minnetonka, Minnesota, United States | Recruiting |
| Legacy Devers Eye Institute | Portland, Oregon, United States | Recruiting |
| Stuart A. Terry, MD PA | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06452316